PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics insider files to sell additional shares under Rule 144. The filing covers a planned sale of 1,286 shares of common stock through Fidelity Brokerage Services on or about 01/08/2026, with an aggregate market value of approximately $98,313.54. These shares were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation.
Over the past three months, Mark Boulding has already sold 11,696 shares of common stock in four transactions, generating total gross proceeds of about $896,531.96. The notice also confirms that the seller represents not knowing any undisclosed material adverse information about the issuer’s operations.
A holder named Mark Boulding has filed a notice under Rule 144 to sell 2,747 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 210,447.74. The shares are listed on NASDAQ and the approximate sale date is 01/08/2026.
The 2,747 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller disposed of common shares in multiple transactions: 2,812 shares on 11/17/2025, 2,266 shares on 01/05/2026, 1,739 shares on 01/06/2026, and 4,879 shares on 01/07/2026, for gross proceeds of 213,690.35, 171,190.18, 133,811.88, and 377,839.55, respectively.
PTC Therapeutics insider Matthew Klein has filed a Form 144 indicating an intent to sell 3,016 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. The shares, with an aggregate market value of $233,691.14, were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.
Over the prior three months, Klein reported additional sales of the issuer’s common stock, including 3,428 shares on 12/02/2025 for gross proceeds of $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about PTC Therapeutics.
Form 144 discloses a planned sale of 3,376 common shares of the issuer’s stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 01/07/2026. The shares have an indicated aggregate market value of $261,381.58, and the issuer has 80,288,305 common shares outstanding.
The shares to be sold were acquired on 01/07/2026 via an option granted on 01/07/2022, with the purchase price paid in cash. Over the prior three months, the seller, Mark Boulding, reported additional sales of common shares: 3,375 shares for $214,094.81 on 10/07/2025, 2,812 shares for $213,690.35 on 11/17/2025, 2,266 shares for $171,190.18 on 01/05/2026, and 1,739 shares for $133,811.88 on 01/06/2026.
PTCT shareholder Lee S. Golden filed a Form 144 notice to potentially sell 642 shares of common stock. The shares are to be sold through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ, with an aggregate market value of 49,744.60, and the issuer has 80,288,305 shares outstanding. These 642 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.
Over the past three months, Golden has sold 1,340 common shares on 01/06/2026 for gross proceeds of 103,109.78. By signing the notice, he represents that he does not know of any material adverse, non‑public information about the issuer’s current or prospective operations, and the form also contemplates the possibility that sales may be made under a Rule 10b5‑1 trading plan.
A Rule 144 notice has been filed for the planned sale of 1,503 shares of common stock, with an aggregate market value of 116,458.15. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 01/07/2026. The shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the filing lists 80,288,305 shares of common stock outstanding. The person named in the notice, Mark Boulding, has also sold common shares of the same issuer during the past three months in several transactions, each with disclosed dates, share amounts, and gross proceeds.
PTCT filed a notice that a security holder plans to sell 1,235 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 01/07/2026 and an aggregate market value of 95,692.49. These shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
The form also notes that Christine Utter sold 1,381 common shares on 01/06/2026 for gross proceeds of 106,264.64 during the past three months. The signer represents they are not aware of undisclosed material adverse information about the issuer.
This notice relates to a planned sale of 52 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026, to be traded on NASDAQ, with an indicated aggregate market value of $4,029.16. The 52 shares were acquired on 01/05/2026 from the issuer via restricted stock vesting as compensation.
Over the prior three months, Neil G. Almstead sold common shares in three transactions: 35,572 shares on 11/24/2025 for $2,852,153.65, 71,928 shares on 11/25/2025 for $6,001,524.59, and 1,279 shares on 01/06/2026 for $98,415.98. Zheng Y. Almstead sold 54 shares of common stock on 01/06/2026 for $4,155.17. The form includes a representation that the seller does not know of undisclosed material adverse information about the issuer.
A holder of PTCT common stock, identified as Eric Pauwels, has filed a notice of proposed sale under Rule 144. The notice covers 1,352 common shares to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $104,758.10 based on the filer’s calculation. The filing notes that 80,288,305 common shares were outstanding and lists the intended sale date as January 7, 2026 on the NASDAQ.
The 1,352 shares to be sold were acquired on January 5, 2026 through restricted stock vesting from the issuer as compensation. The notice also details prior sales of the issuer’s common stock by the same seller during the past three months, including 40,290 shares on December 17, 2025, 3,202 shares on December 18, 2025, 20,508 shares on December 19, 2025, and 1,789 shares on January 6, 2026, for gross proceeds of $3,038,755.33, $240,354.49, $1,584,387.54, and $137,659.26, respectively.
PTC Therapeutics insider Neil G. Almstead filed a Form 144 to potentially sell 1,026 shares of common stock through Fidelity Brokerage Services on NASDAQ around 01/07/2026. The filing notes that these shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the company had 80,288,305 common shares outstanding. Over the prior three months, Neil G. Almstead reported selling 35,572 shares for gross proceeds of 2,852,153.65 on 11/24/2025, 71,928 shares for 6,001,524.59 on 11/25/2025, and 1,279 shares for 98,415.98 on 01/06/2026. Zheng Y. Almstead reported selling 54 shares for 4,155.17 on 01/06/2026.